Improving Alzheimer's disease phase II clinical trials

Alzheimer's and Dementia

Volumn 9, Issue 1, 2013, Pages 39-49

  Greenberg, Barry D ^a   Carrillo, Maria C ^b   Ryan, J Michael ^c   Gold, Michael ^d   Gallagher, Kim ^e   Grundman, Michael ^f   Berman, Robert M ^g   Ashwood, Timothy ^h   Siemers, Eric R ⁱ  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ALZHEIMER'S ASSOCIATION   (United States)

^c PFIZER INC   (United States)

^d Allon Therapeutics   (Canada)

^e GE HEALTHCARE   (United States)

^f Global R and D Partners LLC   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Alzheimer's disease; Clinical assessment; Clinical trials; Drug development; Longitudinal study

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; ATORVASTATIN; AXCL 06; BAPINEUZUMAB; DIMEBON; DOCOSAHEXAENOIC ACID; DONEPEZIL; GALANTAMINE; HOMOCYSTEINE; HOMOTAURINE; HUPERZINE A; IMMUNOGLOBULIN G; LETEPRINIM; MEMANTINE; PHENSERINE; PHYSOSTIGMINE; PLACEBO; RIVASTIGMINE; ROSIGLITAZONE; SEMAGACESTAT; SOLANEZUMAB; TACRINE; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITION; DAILY LIFE ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HUMAN; HYPERINSULINEMIA; MEMORY; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SPATIAL LEARNING;

EID: 84872120012     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.02.002     Document Type: Note

References (77)

1. A.D. Schachter, and M.F. Ramoni Clinical forecasting in drug development Nat Rev Drug Discov 6 2007 107 108
2. K.I. Kaitin, and J.A. DiMasi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009 Clin Pharmacol Ther 89 2011 183 188
3. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 2004 711 715
4. F. Coelho, and J. Birks Physostigmine for Alzheimer's disease Cochrane Database Syst Rev 2001 CD001499
5. M.L. Crismon Tacrine: first drug approved for Alzheimer's disease Ann Pharmacother 28 1994 744 751
6. J.B. Melo, P. Agostinho, and C.R. Oliveira Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide Neurosci Res 45 2003 117 127
7. G.H. Suh, S.H. Ryu, D.W. Lee, C. Han, Y.S. Ju, and B.S. Kee Cholinesterase inhibitors for Alzheimer disease: do they provide more than symptomatic benefits? Am J Geriatr Psychiatry 19 2011 266 273
8. M. Holmes, D. Maysinger, A. Foerster, E. Pertens, C. Barlas, and J. Diamond Neotrofin, a novel purine that induces NGF-dependent nociceptive nerve sprouting but not hyperalgesia in adult rat skin Mol Cell Neurosci 24 2003 568 580
9. M. Grundman, E. Capparelli, H.T. Kim, J.C. Morris, M. Farlow, and E.H. Rubin A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients Life Sci 73 2003 539 553
10. S.G. Potkin, G. Alva, D. Keator, D. Carreon, K. Fleming, and J.H. Fallon Brain metabolic effects of Neotrofin in patients with Alzheimer's disease Brain Res 951 2002 87 95
11. K.T. Shaw, T. Utsuki, J. Rogers, Q.S. Yu, K. Sambamurti, and A. Brossi Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development Proc Natl Acad Sci U S A 98 2001 7605 7610
12. A. Kadir, N. Andreasen, O. Almkvist, A. Wall, A. Forsberg, and H. Engler Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease Ann Neurol 63 2008 621 631
13. B. Winblad, E. Giacobini, L. Frolich, L.T. Friedhoff, G. Bruinsma, and R.E. Becker Phenserine efficacy in Alzheimer's disease J Alzheimers Dis 22 2010 1201 1208
14. T. Kukar, S. Prescott, J.L. Eriksen, V. Holloway, M.P. Murphy, and E.H. Koo Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice BMC Neurosci 8 2007 54
15. D.R. Galasko, N. Graff-Radford, S. May, S. Hendrix, B.A. Cottrell, and S.A. Sagi Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer Dis Assoc Disord 21 2007 292 299
16. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, and E.A. Swabb Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
17. X.D. Wang, J.M. Zhang, H.H. Yang, and G.Y. Hu Modulation of NMDA receptor by huperzine A in rat cerebral cortex Zhongguo Yao Li Xue Bao 20 1999 31 35
18. J.W. Ye, J.X. Cai, L.M. Wang, and X.C. Tang Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment J Pharmacol Exp Ther 288 1999 814 819
19. R. Wang, and X.C. Tang Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease Neurosignals 14 2005 71 82
20. Z. Zhang, X. Wang, Q. Chen, L. Shu, J. Wang, and G. Shan Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial [in Chinese] Zhonghua Yi Xue Za Zhi 82 2002 941 944
21. M.S. Rafii, S. Walsh, J.T. Little, K. Behan, B. Reynolds, and C. Ward A phase II trial of huperzine A in mild to moderate Alzheimer disease Neurology 76 2011 1389 1394
22. H.Y. Kim, Y. Kim, G. Han, and D.J. Kim Regulation of in vitro Abeta1-40 aggregation mediated by small molecules J Alzheimers Dis 22 2010 73 85
23. F. Gervais, J. Paquette, C. Morissette, P. Krzywkowski, M. Yu, and M. Azzi Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis Neurobiol Aging 28 2007 537 547
24. P.S. Aisen, S. Gauthier, B. Vellas, R. Briand, D. Saumier, and J. Laurin Alzhemed: a potential treatment for Alzheimer's disease Curr Alzheimer Res 4 2007 473 478
25. D. Saumier, A. Duong, D. Haine, D. Garceau, and J. Sampalis Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study J Nutr Health Aging 13 2009 808 812
26. P.S. Aisen, D. Saumier, R. Briand, J. Laurin, F. Gervais, and P. Tremblay A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology 67 2006 1757 1763
27. A. Burns, and R. Jacoby Dimebon in Alzheimer's disease: old drug for new indication Lancet 372 2008 179 180
28. N.N. Lermontova, A.E. Redkozubov, E.F. Shevtsova, T.P. Serkova, E.G. Kireeva, and S.O. Bachurin Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels Bull Exp Biol Med 132 2001 1079 1083
29. R.S. Doody, S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, and S.O. Bachurin Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet 372 2008 207 215
30. J. Du, J. Chang, S. Guo, Q. Zhang, and Z. Wang ApoE 4 reduces the expression of Abeta degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons Neurosci Lett 464 2009 140 145
31. S. Craft, S. Asthana, G. Schellenberg, M. Cherrier, L.D. Baker, and J. Newcomer Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender Neuroendocrinology 70 1999 146 152
32. M.A. Reger, G.S. Watson, W.H. Frey II, L.D. Baker, B. Cholerton, and M.L. Keeling Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype Neurobiol Aging 27 2006 451 458
33. G.S. Watson, B.A. Cholerton, M.A. Reger, L.D. Baker, S.R. Plymate, and S. Asthana Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study Am J Geriatr Psychiatry 13 2005 950 958
34. M.E. Risner, A.M. Saunders, J.F. Altman, G.C. Ormandy, S. Craft, and I.M. Foley Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease Pharmacogenomics J 6 2006 246 254
35. M. Gold, C. Alderton, M. Zvartau-Hind, S. Egginton, A.M. Saunders, and M. Irizarry Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study Dement Geriatr Cogn Disord 30 2010 131 146
36. R.J. Bateman, E.R. Siemers, K.G. Mawuenyega, G. Wen, K.R. Browning, and W.C. Sigurdson A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system Ann Neurol 66 2009 48 54
37. E. Portelius, R.A. Dean, M.K. Gustavsson, U. Andreasson, H. Zetterberg, and E. Siemers A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Alzheimers Res Ther 2 2010 7
38. A.S. Fleisher, R. Raman, E.R. Siemers, L. Becerra, C.M. Clark, and R.A. Dean Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol 65 2008 1031 1038
39. G.P. Jarvik, E.M. Wijsman, W.A. Kukull, G.D. Schellenberg, C. Yu, and E.B. Larson Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study Neurology 45 1995 1092 1096
40. A. Lehtonen, and S. Luutonen High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia Age Ageing 15 1986 267 270
41. C. Czech, H. Forstl, F. Hentschel, U. Monning, C. Besthorn, and C. Geiger-Kabisch Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change Eur Arch Psychiatry Clin Neurosci 243 1994 291 292
42. F. Mahieux, R. Couderc, A. Moulignier, S. Bailleul, N. Podrabinek, and J. Laudet Isoform 4 of apolipoprotein E and Alzheimer disease. Specificity and clinical study [in French] Rev Neurol (Paris) 151 1995 231 239
43. M. Sabbagh, H.R. Zahiri, J. Ceimo, K. Cooper, W. Gaul, and D. Connor Is there a characteristic lipid profile in Alzheimer's disease? J Alzheimers Dis 6 2004 585 589 discussion 673-81
44. M.N. Sabbagh, S. Sandhu, H. Kolody, T. Lahti, N.B. Silverberg, and D.L. Sparks Studies on the effect of the apolipoprotein E genotype on the lipid profile in Alzheimer's disease Curr Alzheimer Res 3 2006 157 160
45. Z.S. Tan, S. Seshadri, A. Beiser, P.W. Wilson, D.P. Kiel, and M. Tocco Plasma total cholesterol level as a risk factor for Alzheimer disease: the FRAMINGHAM Study Arch Intern Med 163 2003 1053 1057
46. D.L. Sparks, M.N. Sabbagh, D.J. Connor, J. Lopez, L.J. Launer, and P. Browne Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results Arch Neurol 62 2005 753 757
47. D.L. Sparks, D.J. Connor, M.N. Sabbagh, R.B. Petersen, J. Lopez, and P. Browne Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial Acta Neurol Scand Suppl 185 2006 3 7
48. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74:956-64.
49. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
50. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 2000 916 919
51. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
52. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, and W.E. Klunk 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 2010 363 372
53. K. Blennow, H. Zetterberg, J. Wei, E. Liu, R. Black, and M. Grundman Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimer's disease Alzheimers Dement 6 Suppl 4 2010 S134 S135 Abstract 03-05-01
54. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, and B.T. Hyman Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement 7 2011 367 385
55. E.R. Siemers, S. Friedrich, R.A. Dean, G. Sethuraman, R. DeMattos, and D. Jennings P4-346: safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease Alzheimers Dement 4 Suppl 4 2008 T774
56. A.C. Klaver, L.M. Patrias, M.P. Coffey, J.M. Finke, and D.A. Loeffler Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding J Neurosci Methods 187 2010 263 269
57. R.C. Dodel, Y. Du, C. Depboylu, H. Hampel, L. Frolich, and A. Haag Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease J Neurol Neurosurg Psychiatry 75 2004 1472 1474
58. N.R. Relkin, P. Szabo, B. Adamiak, T. Burgut, C. Monthe, and R.W. Lent 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease Neurobiol Aging 30 2009 1728 1736
59. J.F. Quinn, R. Raman, R.G. Thomas, K. Yurko-Mauro, E.B. Nelson, and C. Van Dyck Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA 304 2010 1903 1911
60. M. Lehmann, C.G. Gottfries, and B. Regland Identification of cognitive impairment in the elderly: homocysteine is an early marker Dement Geriatr Cogn Disord 10 1999 12 20
61. J.M. Kim, R. Stewart, S.W. Kim, I.S. Shin, S.J. Yang, and H.Y. Shin Changes in folate, vitamin B12 and homocysteine associated with incident dementia J Neurol Neurosurg Psychiatry 79 2008 864 868
62. R. Obeid, and W. Herrmann Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia FEBS Lett 580 2006 2994 3005
63. S. Seshadri Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease? J Alzheimers Dis 9 2006 393 398
64. P.S. Aisen, S. Andrieu, C. Sampaio, M. Carrillo, Z.S. Khachaturian, and B. Dubois Report of the task force on designing clinical trials in early (predementia) AD Neurology 76 2011 280 286
65. C.C. Peck, D.B. Rubin, and L.B. Sheiner Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval Clin Pharmacol Ther 73 2003 481 490
66. S. Leonov, and S. Miller An adaptive optimal design for the E(max) model and its application in clinical trials J Biopharm Stat 19 2009 360 385
67. C.R. Jack Jr., V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 Pt 5 2009 1355 1365
68. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
69. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
70. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
71. S.J. Cano, H.B. Posner, M.L. Moline, S.W. Hurt, J. Swartz, and T. Hsu The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts J Neurol Neurosurg Psychiatry 81 2010 1363 1368
72. M. Grundman, R.C. Petersen, S.H. Ferris, R.G. Thomas, P.S. Aisen, and D.A. Bennett Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials Arch Neurol 61 2004 59 66
73. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, and J. Harrison Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 2008 779 786
74. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234
75. R. Craig-Schapiro, R.J. Perrin, C.M. Roe, C. Xiong, D. Carter, and N.J. Cairns YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease Biol Psychiatry 68 2010 903 912
76. B.J. Snider, A.M. Fagan, C. Roe, A.R. Shah, E.A. Grant, and C. Xiong Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type Arch Neurol 66 2009 638 645
77. Alzheimer's Disease International World Alzheimer's Report 2009 25 46